Journal of Medicinal Chemistry · 2014 · 44 citations · 26 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsFragment-based Drug DesignFragment-based Lead DiscoveryHit-to-lead OptimizationImmunomodulatory DrugsLigand-based DesignT Cell PharmacologyDose TolerabilityKinase Inhibitor Library DesignProperty-based Drug DesignRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis Therapy
Protein kinase Cθ (PKCθ) regulates a key step in the activation of T cells. On the basis of its mechanism of action, inhibition of this kinase is hypothesized to serve as an effective therapy for autoimmune diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis. Herein, the discovery of a small molecule PKCθ inhibitor is described, starting from a fragment hit 1 and advancing to compound 41 through the use of structure-based drug design. Compound 41 demonstrates excellent in vitro activity, good oral pharmacokinetics, and efficacy in both an acute in vivo mechanistic model and a chronic in vivo disease model but suffers from tolerability issues upon chronic dosing.
26
PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes
Zuoming Sun, Chris Arendt, Wilfried Ellmeier et al. · Nature · 2000 · 894 citations
PKC-α regulates cardiac contractility and propensity toward heart failure
Julian C. Braz, Kimberly N. Gregory, Anand Pathak et al. · Nature Medicine · 2004 · 593 citations
Medicine, Cardiology, Physiology +12
Protein Kinase C-θ Mediates Negative Feedback on Regulatory T Cell Function
Alexandra Zanin‐Zhorov, Yi Ding, Sudha Kumari et al. · Science · 2010 · 282 citations · Full text